PRESS RELEASE published on 05/04/2023 at 12:30, 3 years 1 month ago Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
PRESS RELEASE published on 05/03/2023 at 22:05, 3 years 1 month ago Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
PRESS RELEASE published on 05/02/2023 at 23:15, 3 years 1 month ago Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
PRESS RELEASE published on 04/20/2023 at 22:05, 3 years 2 months ago Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
PRESS RELEASE published on 04/20/2023 at 13:30, 3 years 2 months ago Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
PRESS RELEASE published on 04/16/2023 at 17:00, 3 years 2 months ago Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following C
PRESS RELEASE published on 04/11/2023 at 13:00, 3 years 2 months ago Moderna Announces Clinical and Program Updates at 4th Vaccines Day
PRESS RELEASE published on 04/06/2023 at 23:00, 3 years 2 months ago MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melan
PRESS RELEASE published on 03/30/2023 at 13:00, 3 years 2 months ago Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
PRESS RELEASE published on 03/24/2023 at 12:30, 3 years 2 months ago Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
Published on 06/20/2026 at 01:00, 1 day 1 hour ago Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 1 day 2 hours ago Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 1 day 21 hours ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 2 days ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 2 days ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/20/2026 at 21:25, 4 hours 34 minutes ago VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 19 hours 59 minutes ago Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 1 day 5 hours ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 20:17, 1 day 5 hours ago 2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Published on 06/19/2026 at 19:01, 1 day 6 hours ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 19:33, 1 day 6 hours ago Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 1 day 6 hours ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 1 day 6 hours ago Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 1 day 6 hours ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
